MATERIALS AND METHODS

Reagents
Oleoyl-LPA (233019) was from Avanti Polar Lipids (Alabaster, AL). Minocycline hydrochloride (475843), marimastat (444289), mouse anti myc-tag (05-724) antibody, mouse anti HA tag (human infl uenzahemagglutinin amino acids 98-106) antibody (05-904), rabbit anti-integrin ␣ 3 (AB1920), and ␤ 1 (04-1109) antibodies were from EMD Millipore (Etobicoke, Ontario, Canada). Doxycycline hyclate (0219895525) was from MP Biomedicals (Solon, OH). Rabbit anti EGFR (sc-03) and rabbit anti E-cadherin (H-108) antibodies were from Santa Cruz (Dallas, TX). Tetracycline hydrochloride (T7660), fatty acid-free albumin from bovine serum (A8806), mouse anti-tubulin (T6074) antibody, and protease inhibitor cocktail (P8340) were from Sigma (St. Louis, MO). The transfection reagent PolyJet (SL100688) was from SignaGen Laboratories (Gaithersburg, MD). Sulfo NHS-SS-biotin (PG82077), streptavidin agarose (20349), G418 sulfate (11811-031), pENTR/ D-TOPO Cloning Kit (K2400-20), and LR clonase enzyme mix (11791-019) were from Life Technologies (Grand Island, NY). PfuUltra DNA polymerase (600385) was from Agilent Technologies (Santa Clara, CA). Anti-GFP antibody was kindly provided by Dr. L. Berthiaume (Department of Cell Biology, University of Alberta, Edmonton, Alberta, Canada), and [ ␥ - 32 P]ATP (BLU002250UC) was from PerkinElmer (Woodbridge, Ontario, Canada). Human recombinant sphingosine kinase-1 (10348) was from Cayman Chemical (Burlington, Ontario, Canada).
Cell culture and lentivirus generation
Human mammary carcinoma cell lines MDA-MB-231 and MCF-7, mouse mammary carcinoma cell line 4T1, human mammary epithelial cell line MCF10A, and human embryonic kidney 293 (HEK293) and HEK293T cell lines were from ATCC (Manassas, VA). MCF10A cells were cultured in DMEM/F12 medium with 10% FBS, 20 ng/ml epidermal growth factor (EGF) , 0.5 g/ml hydrocortisone, 100 ng/ml cholera toxin, and 10 g/ml insulin. Other cell lines were maintained in DMEM supplemented with 10% FBS. C-terminus myc-tagged human LPP1, LPP2, and LPP3 sequences ( plpp1 , plpp2 , and plpp3 genes, respectively) were generated by PCR using cDNA from HEK293 cells. They were fi rst cloned into the pENTR/D-TOPO vector and then the lentiviral destination vector pLenti-PGK-Neo-DEST (Addgene19067) carrying a neomycin selection marker through LR recombination using Gateway® Technology. Lentivirus was generated as described previously ( 20 ) by cotransfecting the lentiviral vector and packaging vectors into HEK293T cells. C-terminus green fl uorescent protein (GFP) -tagged human LPP1, LPP2, and LPP3 were transiently expressed by using pEZY3 plasmid. Human LPP1, LPP2, and LPP3 sequences were fi rst cloned into pENTR1A-GFP-N2 vector (Addgene 19364) between Hind III and Sac II sites, and then recombinated into the pEZY3 vector (Addgene 18672) through LR reaction. membranes or internal membranes, respectively ( 22 ) . LPPs dephosphorylate a wide variety of lipid phosphates and pyrophosphates ( 20, 23 ) . One of their major functions is to dephosphorylate extracellular LPA and possibly sphingosine 1-phosphate (S1P). Signifi cantly, the activities of LPP1 and LPP3 are decreased in many cancers ( 2, 20 ) , which together with increased ATX activity ( 4 ), exposes tumors to higher extracellular LPA concentrations. Therefore, an alternative way to reduce LPA signaling in various infl ammatory conditions including cancers is by increasing the low expressions of LPP1 and LPP3, which are often observed in different malignancies ( 20, (24) (25) (26) . So far, it has been established that gonadotropin-releasing hormone increases LPP activity and LPP3 expression in ovarian cancer cells ( 27 ) . Overexpression of LPP1 in ovarian cancer cell lines increases LPA hydrolysis, which is associated with a marked inhibition of cell proliferation and colony-forming activity and increased apoptosis ( 28 ) . In SKOV3 and OVCAR-3 ovarian cancer cells, LPP3 overexpression promotes extracellular LPA hydrolysis, decreases LPA-stimulated colony formation, and decreases tumor growth in mice ( 29 ) . Similarly, increasing the low expression of LPP1 expression in breast and thyroid cancer cells increases the dephosphorylation of extracellular LPA and also attenuates signaling downstream of LPA and other G-protein-coupled receptors ( 23 ) . These effects resulted in a dramatic suppression in breast and thyroid tumor growth in mouse models ( 23 ) .
Preparation
However, designing therapies that will increase the activity of an enzyme represents much more of a challenge compared with creating an enzyme inhibitor. During our previous work, we used a doxycycline-inducible promoter to express LPP1 in the cancer cells ( 23 ) . We observed that treating cancer cells with increasing doxycycline concentrations enhanced the degradation of exogenous LPA, even in those cells that did not express recombinant LPP1. We, therefore, initiated the present work to elucidate this new effect of doxycycline.
Tetracyclines were discovered in 1940s, and they have developed into a family of broad-spectrum antibiotics with activities against bacteria, chlamydiae, mycoplasmas, rickettsiae, and protozoan parasites ( 30 ) . The bacteriostatic activity is caused by preventing the binding of aminoacyl tRNA to ribosomes, which is necessary for protein synthesis ( 31 ) . It is also well documented that tetracyclines inhibit matrix metalloproteinase (MMP) activities ( 32 ) . In the present study, we demonstrate for the fi rst time that doxycycline increases the degradation of extracellular LPA in multiple cell lines through enhancing the stabilities of LPP1, LPP2, and LPP3 and the expression of these enzymes on the plasma membrane. The physiological relevance of these fi ndings was demonstrated because doxycycline also increased the rate of LPA clearance from the circulation of rats, and it decreased the steady-state concentrations of LPA and S1P in the plasma of mice. The present work, therefore, establishes a novel effect of tetracyclines in decreasing the circulating levels of LPA through increasing the degradation of extracellular LPA. This property could decrease excessive signaling by LPA through its receptors.
Measurement of plasma LPA and S1P concentrations
Female BALB/c mice (22 ± 2 g) were housed with free access to water and food (7001 Teklad 4% fat diet) and pretreated with 100 mg/kg/day doxycycline for 3 days through ip injection. Mice were euthanized, and blood was collected through the heart using an EDTA-coated syringe. Plasma LPA and S1P concentrations were measured as described previously ( 17 ) . Blood samples were centrifuged at 14,000 rpm for 1 min, and plasma was collected. Plasma was treated with internal standards (isotope labeled C17:0-LPA and [ 13 C 2 D 2 ]S1P), and lipid phosphates were extracted into butan-1-ol. Lysophospholipids were measured by LC/MS using electrospray ionization in the negative mode using an Agilent 1200 series LC system coupled to a 3200 QTRAP mass spectrometer (AB Sciex, Concord, Ontario, Canada). The concentrations of different LPA species (C16:0-LPA, C20:4-LPA, C18:2-LPA, C18:0-LPA, and C18:1-LPA) were summed as total LPA concentration in plasma.
Statistical analysis
Results were analyzed by Student's t -test or by ANOVA for multiple comparisons followed by Student-Newman-Keuls test. P < 0.05 was considered statistically signifi cant.
RESULTS
Tetracyclines increased LPP activity in multiple cell lines
During our previous work ( 23 ), we used a doxycyclineinducible promoter to express LPP1 in lentivirus-transduced cells. We observed that doxycycline treatment for 24 h increased the dephosphorylation of exogenous [ ( Fig. 1A ). Because LPP1 and LPP3 activities are decreased in many types of cancer cells, we next determined if doxycycline increased LPP activity in breast cancer cell lines. Treatment with 1 to 50 g/ml (2 to 100 M) doxycycline for 24 h increased dephosphorylation of extracellular LPA in human MDA-MB-231 and MCF-7 and mouse 4T1 breast cancer cell lines ( Fig. 1B-D ) . In nontransformed human mammary epithelial MCF10A cell line, a 48 h treatment with doxycycline was required to increase LPP activity ( Fig. 1E ) . We then treated MDA-MB-231 and 4T1 cells with 1 g/ml tetracycline (2.1 M) or 1 g/ml minocycline (2.0 M) and found that ecto-LPP activity was also increased by these two tetracyclines (supplementary Fig. 1A , B). These combined results demonstrate that tetraycyclines increased ecto-LPP activity in multiple cell types. To determine whether the effect of doxycycline resulted from the direct activation of LPPs, we measured the dephosphorylation of exogenous LPA at different times after incubation with 1 g/ml (2 M) doxycycline. LPP activity did not increase until after ‫ف‬ 20 h of doxycycline treatment ( Fig. 1F ) . These results establish that doxycycline exerts a long-term effect rather than a direct activation of LPP activity.
Because tetracyclines inhibit MMP activity, we determined whether MMP activity controls LPP activity and thus the degradation of LPA. Treatment with 5 M marimastat, a pan MMP inhibitor, for 24 h did not change ecto-LPP activity in MDA-MB-231 cells ( Fig. 1F ) . The IC 50 of S1P and total LPP activity against [ 3 H]phosphatidate (PA) were measured as described by Jasinska et al. ( 33 ) .
Real-time PCR and Western blotting
LPP1, LPP2, and LPP3 mRNA levels were determined by quantitative RT-PCR using GAPDH as a reference mRNA. Protein levels were measured by Western blotting as described previously ( 23 ) . Immunoblots were analyzed by Odyssey infrared imaging system (LI-COR Biosciences).
Expression of LPPs on the plasma membrane
The expression of plasma membrane proteins was determined by tagging the exposed proteins with a noncell permeable biotinylation reagent ( 35 ) . Briefl y, cells were cultured in 10 cm dishes and pretreated with or without doxycycline (0.5-2 g/ml) for 24 h. Cells were placed on ice for 20 min and washed with ice-cold PBS. Cells were incubated with 0.4 mg/ml Sulfo-NHS-SS-biotin in PBS for 30 min on ice and then washed three times with quenching buffer (50 mM glycine in PBS, pH 7.4) and incubated on ice in quenching buffer for 15 min. Cells were washed with PBS and lysed in RIPA buffer. After adjusting the protein concentrations of cell lysates, biotinylated proteins were precipitated using 30 l streptavidin agarose. The LPPs were resolved by SDS-PAGE and revealed by immunoblotting.
LPA and S1P clearance in the circulation and whole blood of rats Sprague Dawley rats (300 ± 20 g) were housed with free access to water and food (7001 Teklad 4% fat diet), and they were then pretreated with 50 mg/kg/day doxycycline through ip injection for 3 days. For measuring LPA clearance, rats were anesthetized with ip injection of 50 mg/kg sodium pentobarbital. A straight incision was made at the middle of the abdomen, and the peritoneal cavity was opened. The portal vein and hepatic artery were exposed by using two cotton swabs to gently lift the liver. After separating the adjacent connective tissues, the portal vein and hepatic artery were ligated using 2.0 silk sutures, and the peritoneal cavity was closed. A straight incision was then made at the middle of neck. The right carotid artery was separated by blunt dissection, and catheterization was performed with a 22 GA catheter. [ 32 P]LPA ( ‫ف‬ 500,000 dpm) was added in 0.5 ml saline containing 0.5 M nonradioactive LPA, 500 M Evans blue, and 0.1% BSA and injected into the circulation through the catheter. About 300 l of blood was collected into an EDTA-coated insulin syringe through the catheter at 30, 60, 90, 120, 180, 240, and 300 s after the injection. Blood samples were centrifuged at 14,000 rpm for 1 min, and 100 l plasma was collected. HCl (1 M, 50 l) was added into the plasma and mixed well. Plasma LPA was extracted twice with 100 l butan-1-ol before measuring the radioactivity. Concentrations of Evans blue were calculated with a standard curve plotted at A620 nm , and this value was used to estimate the volume of circulation and the amount of [ For measuring LPA and S1P degradation in whole blood in vitro, rats were injected ip with vehicle or 50 mg/kg/day of doxycycline for 3 days. They were anesthetized with ip injection of 50 mg/kg sodium pentobarbital. Blood was collected into an EDTAcoated syringe by right carotid artery catheterization. [ ]S1P were injected into the whole blood at ‫ف‬ 50,000 dpm/ml and incubated at 37°C for 1, 5, 10, 20, and 30 min. After adding 1 M HCl, LPA and S1P in the whole blood were extracted with butanol and radioactivity determined. ( Fig. 2A ) ( Fig. 2B-D ) .
Doxycycline increased the protein levels of LPP1, LPP2, and LPP3 and expression on the plasma membrane
Because existing antibodies are not very effective in detecting endogenous levels of LPPs in cell lysates, we established three stable MDA-MB-231 cell lines expressing myc-tagged human LPP1, LPP2, and LPP3 by using lentivirus. Treatment with 1 g/ml doxycycline for 24 h increased the expressions of myc-tagged LPP1, LPP2, and LPP3 ( Fig. 3A , B ) . However, treatment with 1-50 g/ml doxycycline for 24 h did not signifi cantly change mRNA levels of LPPs in both normal ( Fig. 3C ) and virus-transduced MDA-MB-231 cells expressing myc-LPP1, LPP2, and LPP3 (supplementary Fig. 3 ). There was no signifi cant change in mRNA levels of LPPs after 3-12 h of treatment with 1 g/ml doxycycline ( Fig. 3D ) . Therefore, doxycycline appears to increase the protein levels of LPPs through a posttranscriptional mechanism.
LPPs that degrade extracellular LPA are located on plasma membrane, and so we determined whether the amount of LPPs on the cell surface was changed by doxycycline. Plasma membrane proteins were labeled by using a noncell permeable biotinylation reagent and concentrated with streptavidin beads. Doxycycline treatment for 24 h signifi cantly increased the amounts of myc-LPPs on plasma membrane ( Fig. 4A , B ) . To determine whether these effects of doxycycline were specifi c to LPPs, we measured the levels of other plasma membrane proteins including integrin-␣ 3, integrin-␤ 1, EGF receptor, and E-cadherin. No signifi cant changes in the expressions of these proteins were found after doxycycline treatment (supplementary Fig. 4A-C) .
Doxycycline enhanced LPP1, LPP2, and LPP3 stability
Because doxycycline needs at least 20 h to increase LPP activity in cells and it did not affect mRNA levels for the LPPs, it seemed likely that doxycycline suppressed LPP degradation. To test this, we treated MDA-MB-231 cells that stably expressed myc-tagged LPP1, LPP2, and LPP3 with 50 g/ml cycloheximide to inhibit protein synthesis. LPP1 and LPP2 levels decreased signifi cantly after 10 h of cycloheximide treatment by ‫ف‬ 35% and 45%, respectively. Degradation of LPP3 was faster than LPP1 and LPP2. LPP3 levels were decreased by ‫ف‬ 45% after treatment for 6 h with cycloheximide. Adding doxycycline together with cycloheximide signifi cantly slowed the degradation of the three LPPs ( Fig. 5A -D ) . Doxycycline also increased the stability of GFP-LPP2 upon cycloheximide treatment in HEK293 cells, which transiently expressed GFP-LPP2 or HA-LPA receptor type 1 (LPAR1). However, doxycycline did not increase the stability of HA-tagged LPAR1 (supplementary Fig. 5A-D) .
Protein levels of LPP1, LPP2, and LPP3 were also elevated by treatment with the lysosome inhibitor NH 4 Cl (50 mM), but not the proteasome inhibitor MG132 (10 M) (supplementary Fig. 6A ), indicating that LPPs are degraded marimastat for MMPs are at nanomolar levels ( 36 ), and 5 M marimastat is more than suffi cient to inhibit different MMP isoforms. Tetracycline had a much higher IC 50 for MMP-2 compared with marimastat: 160 M versus 2.3 nM (supplementary Fig. 2A, B) . Tetracyclines at 10 g/ml (21 M) did not change the amounts of secretion of MMP-2 and MMP-9 (supplementary Fig. 2C ). These results indicated that the tetracycline-induced changes in LPP activity do not result from MMP inhibition.
Doxycycline also increased the total LPP activity in cell lysates. In normal MDA-MB-231 cells, treatment with 5 g/ml (10 M) doxycycline for 48 h caused a small ( ‫ف‬ 16%) but consistent increase in total LPP activity concentrations of 2 M did not change lysosmal pH, and this contrasted with the effects of 50 mM NH 4 Cl or 20 µM chloroquine, which increased lysosomal pH from about 4.2 to 10.8 and 6.8, respectively (supplementary Fig. 6B ).
in lysosomes. We then determine whether doxycycline decreased the degradation of the LPPs by increasing lysosomal pH using a ratiometric probe, LysoSensor™ Yellow/Blue DND-160 (Life Technologies). Doxycycline at min, and 18% versus 14% at 20 min in control and doxycycline groups, respectively.
The dephosphorylation of S1P in the circulation differed signifi cantly from that of LPA. First, S1P was not removed rapidly by the liver. In fact, ligation and exclusion of the liver from the circulation increased the disappearance of [ 32 P]S1P ( Fig. 6C ) . The half-life of injected [ 32 P] S1P in whole blood was about 1 min, and doxycycline treatment of rats did not increase the removal of S1P from the circulation or the dephosphorylation of S1P in whole blood ( Fig. 6D, E ) .
Dephosphorylation of exogenous [ 32 P]S1P by native MDA-MB-231 cells was also not changed signifi cantly by doxycycline (supplementary Fig. 7A) . To explain this, we transiently expressed GFP-tagged human LPP1, LPP2, and LPP3 in HEK293 cells using the equal amount (0.75 g/ sample) of plasmids to achieve comparable expression levels of LPPs (supplementary Fig. 7B ) and compared their respective activities against LPA and S1P. All three LPPs signifi cantly increased LPA degradation, with the order of potency LPP3 > LPP1 > LPP2 (supplementary Fig. 7C ). However, among the LPPs, LPP3 showed the greatest effect on S1P degradation, whereas overexpression of LPP1 and LPP2 produced limited increases of S1P dephosphorylation (supplementary Fig. 7D ). Our result showed that LPP3 mRNA levels in MDA-MB-231 breast cancer cell line were ‫ف‬ 5-fold lower than the nontransformed MCF10A cell line (supplementary Fig. 7E ), indicating that MDA-MB-231 may have a very low endogenous LPP3 level, which was not able to signifi cantly increase S1P degradation even after doxycycline treatment. HEK293 cells overexpressing GFP-LPP3 showed a small but signifi cant increase of S1P dephosphorylation by doxycycline (supplementary Fig. 7F ).
To further support these results, we treated mice with 100 mg/kg/day doxycycline, and this signifi cantly decreased the total concentration of LPA species in plasma by ‫ف‬ 38% ( Fig. 6F ) . Doxycycline also decreased plasma SIP concentration by ‫ف‬ 42% ( Fig. 6F ) .
DISCUSSION
In the present study, we report for the fi rst time doxycycline increases the degradation of exogenous LPA by increasing the expressions of LPP1, LPP2, and LPP3 on the surface of cells. This increases the "ecto-activity" of the LPPs in degrading extracellular LPA. The mechanism for this effect involved the action of doxycycline in increasing the protein levels of LPP1, LPP2, and LPP3 by delaying their degradations. These results do not depend on the use of an myc-tag to identify the LPPs because doxycycline also increased the stability of GFP-tagged LPP2. The effect was specifi c because there was no effect of doxycycline on other plasma membrane proteins including integrin-␣ 3, integrin-␤ 1, EGF receptor, E-cadherin, and also HA-tagged LPAR1.
LPPs are plasma membrane proteins, which are likely to be degraded in lysosomes when they are internalized. This is compatible with the lack of effect of the proteasome We also tested whether doxycycline changes the cycling of LPPs between cytoplasm and plasma membrane by using a biotinylation method ( 37 ) . We were unable to detect signifi cant effects of doxycycline on the transportation of LPPs to cell surface or the recycling of LPPs (results not shown).
Doxycycline increased LPA clearance from the circulation of rats and in whole blood and decreased plasma LPA and S1P concentrations in mice
The importance of LPP1 in removing LPA from the circulation was demonstrated in LPP1 hypomorph mice ( 38 ) . We, therefore, tested whether doxycycline could increase LPA clearance from the circulation by increasing LPP activity. Salous et al. ( 39 ) reported that the majority of intravenously injected LPA in mice is taken up by the liver, resulting in a rapid clearance of plasma LPA with the halflife of <30 s. Ligation of the dual hepatic blood supply signifi cantly attenuated the rate of removal of intravenously administered LPA ( 39 ) . We observed similar results in rats because 90% of [ 32 P]LPA injected into the rat circulation was cleared within 30 s ( Fig. 6A ). The [ 32 P]LPA that accumulated in liver accounted for ‫ف‬ 77% of that distributed among major organs (heart, liver, spleen, lung, kidney, and brain). Ligation of portal vein and hepatic artery completely eliminated the accumulation of [ ( Fig. 6A ) . Consequently, we chose this strategy for measuring the effects of doxycycline on the LPP-dependent component of LPA clearance from the circulation. The clearance of [ 32 P]LPA from the plasma was increased from 61% to 79% at 30 s and from 75% to 85% at 60 s after injection of [ 32 P]LPA, in the doxycycline-treated rats compared with the controls ( Fig. 6A ) .
We also measured LPA dephosphorylation in whole blood collected from control and doxycycline-treated rats because LPPs are expressed on blood cells. Doxycycline increased LPA dephosphorylation in the blood relative to control rats ( Fig. 6B ). [ 32 P]LPA remaining in the whole blood was 48% versus 39% at 5 min, 30% versus 23% at 10 the circulation in rats and decreased the steady-state concentrations of LPA in the plasma of mice.
The kinetics of the turnover of S1P in the circulation differed from that in LPA. S1P was not cleared rapidly by the liver. Doxycycline treatment did not increase S1P dephosphorylation signifi cantly in the circulation or in whole blood. This is probably explained because dephosphorylation of extracellular S1P depends on the expression of LPP3, with LPP1 and LPP2 having little effect. These results indicate that although the LPPs show relatively little specifi city for different lipid phosphates when these are in detergent micelles ( 40 ) , there does appear to be selectivity for the ecto-activities in intact cells. Our conclusion that LPP3 acts preferentially on extracellular S1P is compatible with studies on the dephosphorylation of FTY720-P, which is an analog of S1P. Lysates from cells that overexpressed LPP1, LPP2, and LPP3 showed that only LPP3 dephosphorylated FTY720-P ( 41 ). LPP3 also acted as an ecto-phosphatase in intact cells in controlling the equilibrium between FTY720 and FTY720-P that was observed in vivo ( 41 ) . inhibitor, MG132, on LPP levels and their increased expression in the presence of NH 4 Cl, which increases lysosomal pH to inhibit lysosomal proteases. However, doxycycline did not increase lysosomal pH. We were also not able to detect an effect of doxycycline on the cycling of the LPPs to and from the plasma membrane. The effects of doxycycline on LPP stability did not depend on the inhibition of MMP activity. The IC 50 of tetracycline was ‫ف‬ 160 M for inhibiting MMP2 activity, which is much higher than that of marimastat, ‫ف‬ 2.3 nM. For other MMP isoforms, the IC 50 of marimastat are within nanomolar range ( 36 ) . We showed that marimastat as high as 5 M did not affect LPP activities.
As a consequence of the doxycycline-induced increase in localization of the LPPs on the plasma membrane, there is an increase in the dephosphorylation of extracellular LPA in multiple cell lines including cancer cells and in whole blood. Signifi cantly, all three LPPs were effective in dephosphorylating extracellular LPA. We established the physiological signifi cance of these fi ndings in vivo by showing that doxycycline increased the clearance of LPA from which we increased LPP1 expression only in the breast cancer cells that were injected into the mice. In this case, there were no signifi cant changes in plasma LPA or S1P in the plasma or breast tumors of the mice ( 23 ) . Also, doxycycline in the present work did not change S1P degradation signifi cantly in MDA-MB-231 cells. This is probably because LPP3 is the major isoform that dephosphorylates exogenous S1P, and the levels of LPP1 and LPP3 are very low in several cancer cells including MDA-MB-231 cells. In fact, the level of LPP3 is approximately fi ve times lower in MDA-MB-231 cells compared with nontransformed mammary epithelial cell line MCF10A. When HEK293 cells overexpressing GFP-LPP3 were treated with doxycycline, the degradation of exogenous S1P signifi cantly increased.
We initiated this study because we observed that 1 g/ml doxycycline or tetracycline, which is the dose commonly used for inducing the Tet-On/Off expression system, Doxycycline did decrease the steady-state level of circulating S1P in treated mice, but this refl ects a balance of S1P production and removal. The effect could have resulted from increased LPP3 expression on plasma membranes throughout the body. It could also have been caused secondary to the decrease in LPA concentrations because LPA can increase S1P release from cells ( 42 ) . However, we think that this is unlikely because decreasing plasma LPA concentrations with an ATX inhibitor did not lower the concentration of circulating S1P ( 13 ) . A further possibility is that tetracyclines exert an anti-infl ammatory effect ( 43, 44 ) , which might indirectly decrease plasma S1P concentrations ( 45 ) . Consequently, doxycycline can decrease the extracellular concentrations of two potent lysophospholipid mediators, LPA and S1P, in part by increasing the combined ecto-activities of LPP1, LPP2, and LPP3. This situation contrasts with our previous study in increased the dephosphorylation of LPA and S1P in intact cells. Therefore, this additional side effect of tetracyclines should be considered when using the Tet-On/Off system. LPA and S1P are very potent signaling molecules, and their signaling effects contribute to the progression of several infl ammatory conditions such as asthma, arthritis, fibrosis, Crohn's disease, ulcerative colitis, atherosclerosis, hepatitis, multiple sclerosis, and cancers. Increasing LPA degradation and decreasing its signaling actions have positive effects as cancer treatments. One strategy for achieving this is to increase the low expression of LPP1 and LPP3 in cancer cells ( 20, 23 ) . However, increasing the activity of enzymes is relatively diffi cult compared with designing enzyme inhibitors. Our present work shows for the fi rst time that doxycycline has the capacity to increase the degradation of extracellular LPA and S1P by increasing the expressions of the LPPs on plasma membranes of cells. This makes it reasonable to consider the application of tetracyclines for such diseases, which involve excessive S1P, and particularly LPA signaling.
